SCGB2A1 and ovarian cancer: Since currently available clinical markers are not completely satisfactory for the prognostic evaluation of patients with EOC, in the present study we extended our molecular and immunohistochemical MGB-2 expression findings previously reported in ovarian cancer [18] and analyzed MGB-2 in a larger cohort of clinically well characterized EOC patients.